FDA OKs First Targeted Drug for HER2-Low Breast Cancer

(MedPage Today) -- The FDA has approved the first targeted therapy for unresectable/metastatic breast cancer in the newly defined low-HER2 subtype.
The approval for trastuzumab deruxtecan (T-DXd, Enhertu) recognizes the recent expansion of the...